Cybin Yönetim
Yönetim kriter kontrolleri 2/4
Şu anda CEO hakkında yeterli bilgiye sahip değiliz.
Anahtar bilgiler
Michael Halstead
İcra Kurulu Başkanı
n/a
Toplam tazminat
| CEO maaş yüzdesi | n/a |
| CEO görev süresi | less than a year |
| CEO sahipliği | n/a |
| Yönetim ortalama görev süresi | 4.9yrs |
| Yönetim Kurulu ortalama görev süresi | 5.1yrs |
Son yönetim güncellemeleri
Recent updates
Anlatı Güncellemesi • Sep 04
HELP: Phase 3 Depression Data And Supportive Policy Tailwinds Will Drive Psychedelic Therapy Demand
Analysts have roughly doubled their fair value estimate for Cybin to about $15.37 per share from about $7.78. They attribute this change to higher assumed revenue growth, improved profit margins and the expectation of a very large future P/E multiple for the psychedelic neuropsych sector, based on recent sector research and regulatory signals.Seeking Alpha • Aug 21
Helus Pharma: An Undervalued Psychedelic Platform Approaching A Major Catalyst
Summary Helus Pharma has built a proprietary psychedelic pipeline that currently spans MDD and GAD. The company has two clinical-stage assets and a broader serotonergic discovery platform. Early HLP003 (oral psilocin) and HLP004 (IM DMT) data suggest efficacy and durability when used as adjunctive therapies, although this comes from small trials. Helus is conducting a phase III trial for HLP003, which could validate its clinical profile and reduce the valuation discount relative to peers. Despite substantial clinical and commercialization risks, the existence of established psychedelic infrastructure and the unmet need in the market, along with Helus’ modest valuation, create an attractive risk-reward opportunity. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Aug 20
HELP: Phase 3 Depression Data And New CEO Appointment Will Drive Repricing
Analysts lifted their fair value estimate for Cybin from $37.57 to $41.62 per share, citing higher projected revenue growth and slightly stronger profit margins supported by growing confidence in regulatory trends and sector readthroughs from recent psychedelic neuropsych research coverage. Analyst Commentary Recent sector research gives investors additional context for how Cybin might be viewed alongside other psychedelic neuropsychiatry companies.Anlatı Güncellemesi • Jul 24
HELP: Phase 3 Depression Readout And Cash Raise Will Drive Repricing
Analysts have reduced their price target on Cybin to reflect a lower fair value estimate of about $37.57. This adjustment is offset by expectations for very large future revenue growth, supported by a reduced future P/E assumption and only modest changes to profit margin and discount rate inputs.
Anlatı Güncellemesi • Jul 10
HELP: Sector Depression Trial Milestones Will Shape This Psychedelic Undervaluation View
Analysts have reduced their price target for Cybin to reflect a revised fair value estimate of about $70.05, citing updated views on long term revenue potential, profit margins, and an adjusted future P/E outlook informed by recent psychedelic sector research on comparable late stage drug developers. Analyst Commentary Recent sector research on late stage psychedelic drug developers is shaping how bullish analysts think about Cybin, especially when they compare it with peers working on deuterated psilocin and similar compounds.Anlatı Güncellemesi • Jun 26
HELP: Policy Momentum On PTSD Treatments Will Drive Future Psychedelic Therapy Demand
Analysts have lowered their Cybin price targets to around $7.78 from about $22.14, citing updated assumptions that include a somewhat higher discount rate, slightly softer long term profit margins, and a reduced but still very large future P/E multiple, partly offset by higher projected revenue growth. What’s in the News for Cybin Cybin completed a follow on equity offering of approximately $50.0 million, issuing 10,309,280 common shares at a price of $4.85 per share, with a stated discount of $0.291 per security.Analiz Makalesi • Jun 17
We Think Cybin (NASDAQ:HELP) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Yeni Anlatı • Apr 05
Psychedelic Therapy Trials Will Face Cash Strain Yet Could Unlock Long Term Upside
Catalysts About Cybin Cybin is a clinical stage biopharmaceutical company developing psychedelic based therapies for major depressive disorder and generalized anxiety disorder. What are the underlying business or industry changes driving this perspective?Yeni Anlatı • Mar 22
Late Stage Psychedelic Therapies And Clinic Partnerships Will Reshape Treatment For Depression And Anxiety
Catalysts About Cybin Cybin is a clinical stage biopharmaceutical company developing psychedelic based therapies for major depressive disorder and generalized anxiety disorder. What are the underlying business or industry changes driving this perspective?Yeni Anlatı • Mar 05
Interventional Psychiatry And Clinic Partnerships Will Support Long Term Psychedelic Treatment Adoption
Catalysts About Cybin Cybin is a clinical stage company developing psychedelic based treatments for major depressive disorder and generalized anxiety disorder. What are the underlying business or industry changes driving this perspective?CEO
Michael Halstead (53 yo)
less than a year
Görev süresi
Mr. Michael I. Halstead, J.D., serves as Chief Executive Officer at Cybin Inc. since August 3, 2026. He is President at Intra-Cellular Therapies, Inc. since March 19, 2024 and had been its General Counsel...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder | 5.8yrs | US$13.57m | 6.18% $ 58.6m | |
| Co-Founder | no data | US$13.56m | 6.14% $ 58.1m | |
| Chief Financial Officer | 5.8yrs | US$1.22m | 0.17% $ 1.6m | |
| Chief Operating Officer | 3.2yrs | US$1.22m | 0.31% $ 2.9m | |
| Chief Medical Officer | 4.9yrs | US$1.32m | 0.31% $ 2.9m | |
| Chief Executive Officer | less than a year | Veri yok | Veri yok | |
| Co-Founder | no data | US$1.19m | Veri yok | |
| Chief Scientific Officer | 5.8yrs | Veri yok | Veri yok | |
| Chief Compliance | 4.9yrs | Veri yok | Veri yok | |
| Chief Legal Officer & Corporate Secretary | 5.8yrs | US$1.12m | 0.24% $ 2.3m | |
| Chief Communications Officers | no data | Veri yok | Veri yok | |
| Chief People Officer | less than a year | Veri yok | Veri yok |
4.9yrs
Ortalama Görev Süresi
52yo
Ortalama Yaş
Deneyimli Yönetim: HELP 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.9 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder | 5.8yrs | US$13.57m | 6.18% $ 58.6m | |
| Co-Founder | 5.8yrs | US$13.56m | 6.14% $ 58.1m | |
| Member of Scientific Advisory Board | less than a year | Veri yok | Veri yok | |
| Lead Independent Director | 5.1yrs | US$239.50k | 0.11% $ 997.1k | |
| Independent Director & Chair of Scientific Advisory Committee | less than a year | US$339.01k | 0.16% $ 1.6m | |
| Independent Director | 5.8yrs | US$239.50k | 0.21% $ 2.0m | |
| Independent Director | 5.8yrs | US$224.50k | 0.21% $ 2.0m | |
| Member of Scientific Advisory Board | less than a year | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | less than a year | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | less than a year | Veri yok | Veri yok | |
| Independent Director | 5.8yrs | US$224.50k | 0.21% $ 2.0m |
5.1yrs
Ortalama Görev Süresi
65yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: HELP 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.1 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/09/14 06:56 |
| Gün Sonu Hisse Fiyatı | 2026/09/14 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2026/03/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Cybin Inc. 15 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| James Molloy | Alliance Global Partners |
| David Martin | Bloom Burton & Co. |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |